Your browser is no longer supported. Please, upgrade your browser.
Settings
ENLV Enlivex Therapeutics Ltd. daily Stock Chart
ENLV [NASD]
Enlivex Therapeutics Ltd.
Index- P/E- EPS (ttm)-1.66 Insider Own0.95% Shs Outstand10.71M Perf Week-4.47%
Market Cap96.25M Forward P/E- EPS next Y- Insider Trans- Shs Float10.02M Perf Month-21.85%
Income-3.20M PEG- EPS next Q- Inst Own0.80% Short Float0.41% Perf Quarter10.13%
Sales- P/S- EPS this Y64.40% Inst Trans-2.28% Short Ratio1.24 Perf Half Y-29.79%
Book/sh1.17 P/B7.68 EPS next Y- ROA-59.40% Target Price9.00 Perf Year-45.73%
Cash/sh1.06 P/C8.44 EPS next 5Y- ROE-67.50% 52W Range6.19 - 30.00 Perf YTD45.17%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-72.60% Beta1.40
Dividend %- Quick Ratio12.10 Sales past 5Y- Gross Margin- 52W Low32.79% ATR1.03
Employees19 Current Ratio12.10 Sales Q/Q- Oper. Margin- RSI (14)39.05 Volatility8.27% 11.35%
OptionableNo Debt/Eq0.00 EPS Q/Q96.90% Profit Margin- Rel Volume0.01 Prev Close8.99
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume33.26K Price8.22
Recom- SMA20-19.37% SMA50-22.72% SMA200-18.90% Volume213 Change-8.53%
Apr-18-19 08:15AM  IMMUNOTHERAPY COMPANY ENLIVEX THERAPEUTICS SELECTED TO RECEIVE AN ADDITIONAL $1 MILLION GRANT BY THE ISRAEL INNOVATION AUTHORITY FOR ITS SEPSIS CLINICAL PROGRAM GlobeNewswire -5.59%
Apr-08-19 07:30AM  IMMUNOTHERAPY COMPANY ENLIVEX THERAPEUTICS COMPLETES PREVIOUSLY ANNOUNCED FINANCING PRICED AT $12.25 PER SHARE, RAISING A TOTAL OF APPROXIMATELY $8.4 MILLION GlobeNewswire
Apr-04-19 09:31AM  ENLIVEX THERAPEUTICS TO PRESENT AT THE 2019 H.C. WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE GlobeNewswire
Mar-26-19 07:30AM  Immunotherapy Company Enlivex Therapeutics Announces Nasdaq Listing Under Symbol ENLV and Closing of Private Placement of Ordinary Shares Priced at $12.25 Per Share GlobeNewswire -10.45%
Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate for the prevention of complications post bone marrow transplantations; treatment of patients that do not respond to steroid treatment upon occurrence of graft vs host disease post bone marrow transplantations; and prevention of cytokine storms, organ damage, and multiple organ failure in sepsis patients. The company also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.